Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use.

Hanifah DavisRachel HeilmannJessica MilchakThomas Delate

Published in: Family practice (2021)

The results of this study provide practitioners with guidance on the patients who are most likely to have a clinically relevant A1C reduction with GLP-1 or SGLT-2 use.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
primary care